O G Rewa1, S M Bagshaw2, X Wang3, R Wald4, O Smith5, J Shapiro4, B McMahon6, K D Liu7, S A Trevino8, L S Chawla9, J L Koyner8. 1. Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. Electronic address: rewa@ualberta.ca. 2. Department of Critical Care Medicine, University of Alberta, Edmonton, AB, Canada. 3. Research Facilitation, Analytics (DIMR), Alberta Health Services, Edmonton, AB, Canada. 4. Department of Nephrology, University of Toronto, Toronto, ON, Canada. 5. Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada. 6. Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. 7. Department of Nephrology, University of California San Francisco, San Francisco, CA, USA. 8. Section of Nephrology Department of Medicine, University of Chicago, Chicago, IL, USA. 9. Department of Medicine, University of California - San Diego, San Diego, CA, USA.
Abstract
PURPOSE: To validate the furosemide stress test (FST) for predicting the progression of acute kidney injury (AKI). MATERIALS AND METHODS: We performed a multicenter, prospective, observational study in patients with stage I or II AKI. The FST (1 mg/kg for loop diuretic naïve patients and 1.5 mg/kg in patients previously exposed to loop diuretics) was administered. Subsequent urinary flow rate (UFR) recorded and predictive ability of urinary output was measured by the area under the curve receiver operatic characteristics (AuROC). Primary outcome was progression to Stage III AKI. Secondary outcomes included in-hospital mortality and adverse events. RESULTS: We studied 92 critically ill patients. 23 patients progressed to stage III AKI and had significantly lower UFR (p < 0.0001). The UFR during the first 2 h was most predictive of progression to stage III AKI (AuROC = 0.87), with an ideal cut-off of less than 200mls, with a sensitivity of 73.9% and specificity of 90.0%. CONCLUSION: In ICU patients without severe CKD with mild AKI, a UFR of less than 200mls in the first 2 h after an FST is predictive of progression to stage III AKI. Future studies should focus on incorporating a FST as part of a clinical decision tool for further management of critically ill patients with AKI.
PURPOSE: To validate the furosemide stress test (FST) for predicting the progression of acute kidney injury (AKI). MATERIALS AND METHODS: We performed a multicenter, prospective, observational study in patients with stage I or II AKI. The FST (1 mg/kg for loop diuretic naïve patients and 1.5 mg/kg in patients previously exposed to loop diuretics) was administered. Subsequent urinary flow rate (UFR) recorded and predictive ability of urinary output was measured by the area under the curve receiver operatic characteristics (AuROC). Primary outcome was progression to Stage III AKI. Secondary outcomes included in-hospital mortality and adverse events. RESULTS: We studied 92 critically ill patients. 23 patients progressed to stage III AKI and had significantly lower UFR (p < 0.0001). The UFR during the first 2 h was most predictive of progression to stage III AKI (AuROC = 0.87), with an ideal cut-off of less than 200mls, with a sensitivity of 73.9% and specificity of 90.0%. CONCLUSION: In ICU patients without severe CKD with mild AKI, a UFR of less than 200mls in the first 2 h after an FST is predictive of progression to stage III AKI. Future studies should focus on incorporating a FST as part of a clinical decision tool for further management of critically ill patients with AKI.
Authors: J L Vincent; R Moreno; J Takala; S Willatts; A De Mendonça; H Bruining; C K Reinhart; P M Suter; L G Thijs Journal: Intensive Care Med Date: 1996-07 Impact factor: 17.440
Authors: Jamie Penk; Katja M Gist; Eric L Wald; Laura Kitzmiller; Tennille N Webb; Yi Li; David S Cooper; Stuart L Goldstein; Rajit K Basu Journal: J Thorac Cardiovasc Surg Date: 2019-01-11 Impact factor: 5.209
Authors: Jay L Koyner; Amit X Garg; Steven G Coca; Kyaw Sint; Heather Thiessen-Philbrook; Uptal D Patel; Michael G Shlipak; Chirag R Parikh Journal: J Am Soc Nephrol Date: 2012-03-01 Impact factor: 10.121
Authors: Oleksa Rewa; Ron Wald; Neill K J Adhikari; Michelle Hladunewich; Stephen Lapinsky; John Muscedere; Sean M Bagshaw; Orla M Smith; Gerald Lebovic; Rottem Kuint; David J Klein Journal: J Crit Care Date: 2015-09-01 Impact factor: 3.425
Authors: Armando Coca; Carmen Aller; Jimmy Reinaldo Sánchez; Ana Lucía Valencia; Elena Bustamante-Munguira; Juan Bustamante-Munguira Journal: Int J Mol Sci Date: 2020-04-27 Impact factor: 5.923